Rizatriptan contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Rizatriptan}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher = | date = | accessdate = }}</ref> | MAXALT is contraindicated in patients with: | ||
* Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions (5.1)]. | |||
* Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions (5.1)]. | |||
* History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions (5.4)]. | |||
* Peripheral vascular disease (PVD) [see Warnings and Precautions (5.5)]. | |||
* Ischemic bowel disease [see Warnings and Precautions (5.5)]. | |||
* Uncontrolled hypertension [see Warnings and Precautions (5.8)]. | |||
* Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3)]. | |||
* Hemiplegic or basilar migraine [see Indications and Usage (1)]. | |||
* Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)]. | |||
* Hypersensitivity to MAXALT or MAXALT-MLT (angioedema and anaphylaxis seen) [see Adverse Reactions (6.2)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 07:10, 10 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
MAXALT is contraindicated in patients with:
- Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions (5.1)].
- Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions (5.1)].
- History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions (5.4)].
- Peripheral vascular disease (PVD) [see Warnings and Precautions (5.5)].
- Ischemic bowel disease [see Warnings and Precautions (5.5)].
- Uncontrolled hypertension [see Warnings and Precautions (5.8)].
- Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3)].
- Hemiplegic or basilar migraine [see Indications and Usage (1)].
- Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].
- Hypersensitivity to MAXALT or MAXALT-MLT (angioedema and anaphylaxis seen) [see Adverse Reactions (6.2)].[1]
References
Adapted from the FDA Package Insert.